NASDAQ:LENZ LENZ Therapeutics Q2 2025 Earnings Report $5.80 +0.57 (+10.90%) Closing price 09/2/2026 04:00 PM EasternExtended Trading$5.78 -0.02 (-0.28%) As of 09/2/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast LENZ Therapeutics EPS ResultsActual EPS-$0.53Consensus EPS -$0.58Beat/MissBeat by +$0.05One Year Ago EPSN/ALENZ Therapeutics Revenue ResultsActual Revenue$5.00 millionExpected Revenue$5.00 millionBeat/MissMet ExpectationsYoY Revenue GrowthN/ALENZ Therapeutics Announcement DetailsQuarterQ2 2025Date7/30/2025TimeBefore Market OpensConference Call DateWednesday, July 30, 2025Conference Call Time8:00AM ETUpcoming EarningsLENZ Therapeutics' Q3 2026 earnings is estimated for Wednesday, November 4, 2026, based on past reporting schedules, with a conference call scheduled at 8:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) LENZ Therapeutics Earnings HeadlinesShort interest alert: Most and least shorted sub-$2B healthcare stocks in Aug 2026September 2 at 1:26 PM | msn.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZSeptember 1 at 5:31 PM | globenewswire.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain. | InvestorPlace (Ad)Brokerages Set LENZ Therapeutics, Inc. (NASDAQ:LENZ) Target Price at $28.80August 29, 2026 | americanbankingnews.comLENZ Therapeutics, Inc. (LENZ) Latest Press Releases & Corporate News - Yahoo FinanceAugust 27, 2026 | finance.yahoo.comLENZ Therapeutics (LENZ) Q2 2026 Earnings Call TranscriptAugust 19, 2026 | finance.yahoo.comSee More LENZ Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like LENZ Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on LENZ Therapeutics and other key companies, straight to your email. Email Address About LENZ TherapeuticsLENZ Therapeutics (NASDAQ:LENZ), a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.View LENZ Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles GitLab’s Earnings Beat Just Gave Software Bulls a New SaaSpocalypse TestLilly’s Merida Deal Shows the GLP-1 King Is Already Thinking Beyond ObesityWendy’s Rally Fades After Trian Steps Back: Was It Ever Real?From High Dividend Growth to High Yield, These 3 Stocks Just Boosted Dividend PayoutsJ.M. Smucker Stock's Rally Has More Than Tariffs Behind ItUlta Beauty’s Earnings Beat Was Stronger Than the Stock’s ReactionNVIDIA’s MediaTek Bet Shows How It Plans to Defend Its AI Moat Upcoming Earnings Ciena (9/3/2026)Oracle (9/8/2026)Adobe (9/10/2026)FedEx (9/17/2026)Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
